

George Cholankeril

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/160580/publications.pdf>

Version: 2024-02-01

102
papers

3,410
citations

186209

28
h-index

161767

54
g-index

104
all docs

104
docs citations

104
times ranked

5314
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018. <i>Journal of General Internal Medicine</i> , 2022, 37, 261-263.	1.3	15
2	Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1438-e1455.	2.4	49
3	Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARS-CoV-2 Infection. <i>Liver Transplantation</i> , 2022, 28, 127-130.	1.3	1
4	Clinical Factors Associated With Lack of Serological Response to SARS-CoV-2 Messenger RNA Vaccine in Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 123-126.	1.3	25
5	Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. <i>Clinical Transplantation</i> , 2022, , e14646.	0.8	1
6	DETECT: Development of Technologies for Early HCC Detection. <i>Gastroenterology</i> , 2022, 163, 21-27.	0.6	4
7	Comparable survival for hepatitis C-related hepatocellular carcinoma after liver transplantation irrespective of viremic status. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
8	Trends in the Prevalence of Hepatitis C Virus Infection based on the Insurance Status in the United States from 2013 to 2018. <i>Liver International</i> , 2022, 42, 340-349.	1.9	5
9	Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. <i>Transplantation Direct</i> , 2022, 8, e1313.	0.8	10
10	Trends in All-Cause and Cause-Specific Mortality Among Individuals With Diabetes Before and During the COVID-19 Pandemic in the U.S.. <i>Diabetes Care</i> , 2022, 45, e107-e109.	4.3	4
11	Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1499-1501.e2.	2.4	38
12	Association of Anti-TNF Therapy With Increased Risk of Acute Cholangitis in Patients With Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1602-1609.	0.9	5
13	Trends in Hospitalizations for <i>Clostridioides difficile</i> Infection in End-Stage Liver Disease, 2005-2014. <i>Digestive Diseases and Sciences</i> , 2021, 66, 296-307.	1.1	6
14	Gender and Racial Differences in Hospitalizations for Primary Biliary Cholangitis in the USA. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1461-1476.	1.1	11
15	Trends in mortality in hepatitis C infection and alcoholic liver disease based on drug overdose in the United States. <i>Journal of Viral Hepatitis</i> , 2021, 28, 436-439.	1.0	0
16	Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1240-1247.e5.	2.4	40
17	Trends in the Mortality of Biliary Tract Cancers Based on Their Anatomical Site in the United States From 2009 to 2018. <i>American Journal of Gastroenterology</i> , 2021, 116, 1053-1062.	0.2	15
18	Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States. <i>Liver International</i> , 2021, 41, 1832-1840.	1.9	35

#	ARTICLE	IF	CITATIONS
19	Current Trends in Liver Transplantation for Alcoholic Hepatitis. <i>Clinics in Liver Disease</i> , 2021, 25, 625-634.	1.0	2
20	Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2664-2666.e2.	2.4	20
21	The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 477-482.	1.3	5
22	Gastrointestinal manifestations of coronavirus disease 2019. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 471-476.	1.3	4
23	NAFLD and HCC: Time to Bridge the Gap. <i>Hepatology</i> , 2021, 74, 2336-2338.	3.6	3
24	Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. <i>Transplant International</i> , 2021, 34, 1971-1983.	0.8	2
25	Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. <i>Hepatology</i> , 2021, 74, 3316-3329.	3.6	75
26	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 747-756.	1.1	2
27	Marginal Allografts in Liver Transplantation Have a Limited Impact on Length of Stay. <i>Clinical Transplantation</i> , 2021, , e14544.	0.8	1
28	Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. <i>Journal of Palliative Medicine</i> , 2020, 23, 97-106.	0.6	13
29	Increasing Mortality Among Patients With Diabetes and Chronic Liver Disease From 2007 to 2017. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 992-994.	2.4	6
30	Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 990-1002.	1.1	17
31	Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality. <i>Liver International</i> , 2020, 40, 815-824.	1.9	26
32	Regional Trends in Mortality from Alcohol-Induced Causes in the United States, 2000-2017. <i>Journal of General Internal Medicine</i> , 2020, 35, 2495-2498.	1.3	1
33	Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 72, 1556-1568.	3.6	70
34	Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. <i>American Journal of Gastroenterology</i> , 2020, 115, 1496-1504.	0.2	40
35	Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00165.	1.3	4
36	Decline in Annual Mortality of Hepatitis C Virus-Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. <i>Gastroenterology</i> , 2020, 159, 1558-1560.e2.	0.6	17

#	ARTICLE	IF	CITATIONS
37	Implementation and Impact of Universal Preprocedure Testing of Patients for COVID-19 Before Endoscopy. <i>Gastroenterology</i> , 2020, 159, 1586-1588.e4.	0.6	25
38	Association of Digestive Symptoms and Hospitalization in Patients With SARS-CoV-2 Infection. <i>American Journal of Gastroenterology</i> , 2020, 115, 1129-1132.	0.2	39
39	The impact of chronic liver disease in patients receiving active pharmacological therapy for opioid use disorder: One-year findings from a prospective cohort study. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107917.	1.6	5
40	High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California. <i>Gastroenterology</i> , 2020, 159, 775-777.	0.6	198
41	Early Impact of COVID-19 on Solid Organ Transplantation in the United States. <i>Transplantation</i> , 2020, 104, 2221-2224.	0.5	68
42	Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection?. <i>American Journal of Gastroenterology</i> , 2020, 115, 1920-1921.	0.2	15
43	Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2019, 69, 1064-1074.	3.6	154
44	Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary. <i>Nutrition and Metabolic Insights</i> , 2019, 12, 117863881984748.	0.8	5
45	Depression is associated with non-alcoholic fatty liver disease among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 590-598.	1.9	62
46	Pre-Operative Delta-MELD is an Independent Predictor of Higher Mortality following Liver Transplantation. <i>Scientific Reports</i> , 2019, 9, 8312.	1.6	9
47	Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 65-65.	1.5	11
48	Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. <i>Gastroenterology</i> , 2019, 157, 1055-1066.e11.	0.6	53
49	Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. <i>Hepatology International</i> , 2019, 13, 205-213.	1.9	63
50	Hepatocellular carcinoma is leading in cancer-related disease burden among hospitalized baby boomers. <i>Annals of Hepatology</i> , 2019, 18, 679-684.	0.6	6
51	Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. <i>Liver International</i> , 2019, 39, 1661-1671.	1.9	32
52	Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017. <i>Diabetologia</i> , 2019, 62, 1185-1194.	2.9	23
53	The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2019, 7, 27.	1.0	36
54	Elevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United States. <i>Liver International</i> , 2019, 39, 1335-1342.	1.9	44

#	ARTICLE	IF	CITATIONS
55	Disparate Trends in Mortality of Etiology-Specific Chronic Liver Diseases Among Hispanic Subpopulations. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1607-1615.e2.	2.4	19
56	Temporal Trends Associated With the Rise in Alcoholic Liver Disease-related Liver Transplantation in the United States. <i>Transplantation</i> , 2019, 103, 131-139.	0.5	23
57	Low-Normal Thyroid Function Is Associated With Advanced Fibrosis Among Adults in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2379-2381.	2.4	35
58	Increasing Trends in Transplantation of HCV-Positive Livers Into Uninfected Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1634-1636.	2.4	15
59	Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019, 25, 399-410.	1.3	24
60	Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 149-156.	0.8	20
61	An Unexpected Colonic Mass. <i>American Journal of Gastroenterology</i> , 2019, 114, 180-181.	0.2	1
62	Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis. <i>Hepatology International</i> , 2019, 13, 84-90.	1.9	21
63	Inpatient Outcomes for Gastrointestinal Bleeding Associated With Percutaneous Coronary Intervention. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 120-126.	1.1	3
64	Recent advances in liver transplantation with HCV seropositive donors. <i>F1000Research</i> , 2019, 8, 2151.	0.8	1
65	Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients. <i>Hepatology</i> , 2018, 68, 792-793.	3.6	1
66	Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1647-1653.	1.1	12
67	Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 965-973.e2.	2.4	28
68	Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1356-1358.	2.4	200
69	Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 452-453.	2.4	34
70	The Role of Vitamin E in the Treatment of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 86.	1.0	87
71	Judicious Use of Lipid Lowering Agents in the Management of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 87.	1.0	14
72	Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 88.	1.0	16

#	ARTICLE	IF	CITATIONS
73	When to Initiate Weight Loss Medications in the NAFLD Population. <i>Diseases</i> (Basel, Switzerland), 2018, 6, 91.	1.0	11
74	Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. <i>Diseases</i> (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	36
75	Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. <i>Gastroenterology</i> , 2018, 155, 1154-1163.e3.	0.6	166
76	Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-7.	0.7	25
77	Case Report of Isoniazid-Related Acute Liver Failure Requiring Liver Transplantation. <i>Diseases</i> (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	1.0	7
78	Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease. <i>Medicines</i> (Basel, Switzerland), 2018, 5, 47.	0.7	18
79	The Role of Cannabinoids in the Setting of Cirrhosis. <i>Medicines</i> (Basel, Switzerland), 2018, 5, 52.	0.7	17
80	Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era. <i>Diseases</i> (Basel, Switzerland), 2018, 6, 62.	1.0	16
81	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1608-1616.	1.0	13
82	Early Liver Transplantation is a Viable Treatment Option in Severe Acute Alcoholic Hepatitis. <i>Alcohol and Alcoholism</i> , 2018, 53, 716-718.	0.9	13
83	Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States. <i>Journal of General Internal Medicine</i> , 2018, 33, 1423-1425.	1.3	4
84	Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-5.	0.7	20
85	Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. <i>World Journal of Gastroenterology</i> , 2018, 24, 315-322.	1.4	15
86	Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 313-315.	2.4	12
87	Proton Pump Inhibitors and the Possible Development of Hepatic Encephalopathy in Cirrhotic Patients: True Association or Residual Confounding?. <i>Gastroenterology</i> , 2017, 152, 2076.	0.6	9
88	Optimal timing for hepatitis C antiviral therapy in the peritransplant period?. <i>Hepatology</i> , 2017, 66, 1004-1004.	3.6	0
89	Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2017, 112, 1495-1505.	0.2	83
90	Direct-Acting Antiviral Therapy and Improvement in Graft Survival of Hepatitis C Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, e349.	0.5	5

#	ARTICLE	IF	CITATIONS
91	Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2915-2922.	1.1	192
92	Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast. <i>Hepatology</i> , 2017, 65, 393-393.	3.6	3
93	Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease. <i>Diseases (Basel, Switzerland)</i> , 2017, 5, 20.	1.0	10
94	The importance of a multidisciplinary approach to hepatocellular carcinoma. <i>Journal of Multidisciplinary Healthcare</i> , 2017, Volume 10, 95-100.	1.1	52
95	Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis. <i>Nutrients</i> , 2017, 9, 1114.	1.7	15
96	Hepatic encephalopathy: what the multidisciplinary team can do. <i>Journal of Multidisciplinary Healthcare</i> , 2017, Volume 10, 113-119.	1.1	6
97	Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 8263-8276.	1.4	514
98	Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. <i>World Journal of Hepatology</i> , 2017, 9, 533.	0.8	140
99	Portomesenteric venous thrombosis complicated by a haemorrhagic shock: a rare complication of laparoscopic gastrectomy. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2016-219167.	0.2	1
100	Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 1-5.	0.7	7
101	Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2505-2515.	1.1	12
102	Trends in Liver Transplantation Multiple Listing Practices Associated With Disparities in Donor Availability: An Endless Pursuit to Implement the Final Rule. <i>Gastroenterology</i> , 2016, 151, 382-386.e2.	0.6	5